Effectiveness and harms of pharmacological interventions for the treatment of delirium in adults in intensive care units after cardiac surgery: a systematic review.
Vivienne Leigh, Cindy Stern, Rosalind M. Elliott, C. Tufanaru
{"title":"Effectiveness and harms of pharmacological interventions for the treatment of delirium in adults in intensive care units after cardiac surgery: a systematic review.","authors":"Vivienne Leigh, Cindy Stern, Rosalind M. Elliott, C. Tufanaru","doi":"10.11124/JBISRIR-D-18-00010","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\nThe objective of this review was to synthesize the best available evidence on the effectiveness and harms of pharmacological interventions for the treatment of delirium in adult patients in the intensive care unit (ICU) after cardiac surgery.\n\n\nINTRODUCTION\nPatients who undergo cardiac surgery are at high risk of delirium (incidence: 50-90%). Delirium has deleterious effects, increasing the risk of death and adversely affecting recovery. Clinical interventional trials have been conducted to prevent and treat postoperative delirium pharmacologically including antipsychotics and sedatives. These trials have provided some evidence about efficacy and influenced clinical decision making. However, much reporting is incomplete and provides biased assessments of efficacy; benefits are emphasized while harms are inadequately reported.\n\n\nINCLUSION CRITERIA\nParticipants were ≥ 16 years, any sex or ethnicity, who were treated postoperatively in a cardiothoracic ICU following cardiac surgery and were identified as having delirium. Any pharmacological intervention for the treatment of delirium was included, regardless of drug classification, dosage, intensity or frequency of administration. Outcomes of interest of this review were: mortality, duration and severity of delirium, use of physical restraints, quality of life, family members' satisfaction with delirium management, duration/severity of the aggressive episode, associated falls, severity of accidental self-harm, pharmacological harms, harms related to over-sedation, ICU length of stay, hospital length of stay (post ICU), total hospital length of stay, need for additional intervention medication and need for rescue medication. Randomized controlled trials were considered first and in their absence, non-randomized controlled trials and quasi-experimental would have been considered, followed by analytical observational studies.\n\n\nMETHODS\nA search was conducted in PubMed, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, Scopus, Epistemonikos, Australian New Zealand Clinical Trials Registry, ClinicalTrials.gov, Clinical Trials in New Zealand, and ProQuest Dissertations and Theses to locate both published and unpublished studies. There was no date limit for the search. A hand search for primary studies published between January 1, 2012 and November 17, 2018 in relevant journals was also conducted. Only studies published in English were considered for inclusion. Two reviewers independently assessed the methodological quality using standardized critical appraisal instruments from JBI and McMaster University. Quantitative data were extracted using the standardized JBI data extraction tool. A meta-analysis was not performed, as there was too much clinical and methodological heterogeneity in the included studies. Results have been presented in a narrative form. Standard GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) evidence assessment of outcomes has been reported.\n\n\nRESULTS\nThree RCTs investigating morphine versus haloperidol (n = 53), ondansetron versus haloperidol (n = 72), and dexmedetomidine versus midazolam (n = 80) were included. Due to heterogeneity and incomplete reporting, a meta-analysis was not feasible. Overall, the methodological quality of these studies was found to be low. Additionally, this review found reporting of harms to be inadequate and superficial for all three studies and did not meet the required standards for harms reporting, as defined by the CONSORT statement extension for harms.\n\n\nCONCLUSIONS\nIt was not possible to draw any valid conclusions regarding the effectiveness of morphine vs haloperidol, ondansetron vs haloperidol or dexmedetomidine vs midazolam in treating delirium after cardiac surgery. This is due to the low number of studies, the poor methodological quality in conducting and reporting and the heterogeneity between the studies.","PeriodicalId":73539,"journal":{"name":"JBI database of systematic reviews and implementation reports","volume":"7 2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI database of systematic reviews and implementation reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBISRIR-D-18-00010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
Abstract
OBJECTIVE
The objective of this review was to synthesize the best available evidence on the effectiveness and harms of pharmacological interventions for the treatment of delirium in adult patients in the intensive care unit (ICU) after cardiac surgery.
INTRODUCTION
Patients who undergo cardiac surgery are at high risk of delirium (incidence: 50-90%). Delirium has deleterious effects, increasing the risk of death and adversely affecting recovery. Clinical interventional trials have been conducted to prevent and treat postoperative delirium pharmacologically including antipsychotics and sedatives. These trials have provided some evidence about efficacy and influenced clinical decision making. However, much reporting is incomplete and provides biased assessments of efficacy; benefits are emphasized while harms are inadequately reported.
INCLUSION CRITERIA
Participants were ≥ 16 years, any sex or ethnicity, who were treated postoperatively in a cardiothoracic ICU following cardiac surgery and were identified as having delirium. Any pharmacological intervention for the treatment of delirium was included, regardless of drug classification, dosage, intensity or frequency of administration. Outcomes of interest of this review were: mortality, duration and severity of delirium, use of physical restraints, quality of life, family members' satisfaction with delirium management, duration/severity of the aggressive episode, associated falls, severity of accidental self-harm, pharmacological harms, harms related to over-sedation, ICU length of stay, hospital length of stay (post ICU), total hospital length of stay, need for additional intervention medication and need for rescue medication. Randomized controlled trials were considered first and in their absence, non-randomized controlled trials and quasi-experimental would have been considered, followed by analytical observational studies.
METHODS
A search was conducted in PubMed, Embase, CINAHL, Web of Science, Cochrane Central Register of Controlled Trials, Scopus, Epistemonikos, Australian New Zealand Clinical Trials Registry, ClinicalTrials.gov, Clinical Trials in New Zealand, and ProQuest Dissertations and Theses to locate both published and unpublished studies. There was no date limit for the search. A hand search for primary studies published between January 1, 2012 and November 17, 2018 in relevant journals was also conducted. Only studies published in English were considered for inclusion. Two reviewers independently assessed the methodological quality using standardized critical appraisal instruments from JBI and McMaster University. Quantitative data were extracted using the standardized JBI data extraction tool. A meta-analysis was not performed, as there was too much clinical and methodological heterogeneity in the included studies. Results have been presented in a narrative form. Standard GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) evidence assessment of outcomes has been reported.
RESULTS
Three RCTs investigating morphine versus haloperidol (n = 53), ondansetron versus haloperidol (n = 72), and dexmedetomidine versus midazolam (n = 80) were included. Due to heterogeneity and incomplete reporting, a meta-analysis was not feasible. Overall, the methodological quality of these studies was found to be low. Additionally, this review found reporting of harms to be inadequate and superficial for all three studies and did not meet the required standards for harms reporting, as defined by the CONSORT statement extension for harms.
CONCLUSIONS
It was not possible to draw any valid conclusions regarding the effectiveness of morphine vs haloperidol, ondansetron vs haloperidol or dexmedetomidine vs midazolam in treating delirium after cardiac surgery. This is due to the low number of studies, the poor methodological quality in conducting and reporting and the heterogeneity between the studies.
目的本综述的目的是综合现有的关于药物干预治疗心脏手术后重症监护病房(ICU)成人患者谵妄的有效性和危害的最佳证据。心脏手术患者谵妄的发生率高(50-90%)。谵妄具有有害的影响,增加死亡的风险并对康复产生不利影响。对术后谵妄进行了包括抗精神病药物和镇静剂在内的药物预防和治疗的临床介入试验。这些试验提供了一些关于疗效的证据,并影响了临床决策。然而,许多报告是不完整的,并提供了有偏见的疗效评估;好处被强调,而危害没有得到充分的报道。入选标准:参与者年龄≥16岁,不分性别或种族,在心脏手术后在心胸重症监护室接受治疗,并确定患有谵妄。任何治疗谵妄的药物干预都包括在内,无论药物分类、剂量、强度或给药频率如何。本综述关注的结果是:死亡率、谵妄的持续时间和严重程度、身体约束的使用、生活质量、家属对谵妄管理的满意度、攻击性发作的持续时间/严重程度、相关跌倒、意外自残的严重程度、药理学危害、过度镇静相关的危害、ICU住院时间、住院时间(ICU后)、总住院时间、额外干预药物的需要和抢救药物的需要。首先考虑随机对照试验,如果没有随机对照试验,则考虑非随机对照试验和准实验,然后考虑分析性观察研究。方法检索PubMed、Embase、CINAHL、Web of Science、Cochrane Central Register of Controlled Trials、Scopus、Epistemonikos、Australian New Zealand ClinicalTrials Registry、ClinicalTrials.gov、ClinicalTrials in New Zealand、ProQuest disserthesis and Theses,查找已发表和未发表的研究。搜索没有日期限制。对2012年1月1日至2018年11月17日在相关期刊上发表的初步研究进行了手工检索。只有以英文发表的研究才被纳入考虑。两位审稿人使用来自JBI和麦克马斯特大学的标准化关键评估工具独立评估方法质量。采用标准化的JBI数据提取工具提取定量数据。由于纳入的研究中存在太多的临床和方法学异质性,因此未进行荟萃分析。结果以叙述的形式呈现。标准GRADE(建议、评估、发展和评价的分级)证据评估结果已被报道。结果纳入吗啡与氟哌啶醇对照(n = 53)、昂丹西酮与氟哌啶醇对照(n = 72)、右美托咪定与咪达唑仑对照(n = 80) 3项随机对照试验。由于异质性和不完整的报告,荟萃分析是不可行的。总体而言,这些研究的方法学质量较低。此外,本综述发现,所有三项研究对危害的报告都是不充分和肤浅的,并且不符合危害报告的要求标准,如CONSORT声明扩展对危害的定义。结论吗啡与氟哌啶醇、昂丹司琼与氟哌啶醇、右美托咪定与咪达唑仑治疗心脏手术后谵妄的有效性尚不能得出有效结论。这是由于研究数量少,进行和报告的方法学质量差以及研究之间的异质性。